Loading...
XOSL
PHO
Market cap174mUSD
Dec 05, Last price  
66.30NOK
1D
3.43%
1Q
7.46%
Jan 2017
57.86%
IPO
-55.20%
Name

Photocure ASA

Chart & Performance

D1W1MN
XOSL:PHO chart
P/E
—
P/S
3.36
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.42%
Rev. gr., 5y
13.29%
Revenues
525m
+4.94%
53,641,000210,320,00099,006,000102,220,00048,428,000177,357,000115,568,000133,823,00083,616,000128,952,000134,717,000143,627,000150,911,000181,510,000281,556,000256,482,000360,540,000393,132,000500,657,000525,388,000
Net income
-5m
L
-38,210,00085,082,000-74,970,000-64,382,000312,382,00018,092,000-7,512,000-47,901,000-58,950,000-24,700,000-36,178,00035,309,000-34,697,000-36,708,00031,832,000-22,403,000-30,897,000-71,857,000979,000-4,810,000
CFO
77m
+58.88%
-70,540,00066,326,000-95,655,000-59,677,000317,444,00015,597,000-34,466,000-54,928,000-99,722,000-6,088,000-21,032,00019,193,000-23,593,000-24,124,00020,655,00015,585,00023,886,000-2,018,00048,309,00076,751,000
Dividend
May 23, 20132 NOK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
URL
https://photocure.com/
IPO date
May 29, 2000
Employees
87
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT